The ability to perform GPC3-targeted imaging using widely distributed gamma cameras could enable broader early detection, staging, and post-therapy monitoring of hepatocellular carcinoma, especially in regions with a high burden of disease but limited access to advanced nuclear medicine technologies. This evidence concerns the gene GPC3 and hepatocellular carcinoma.